N-methyl-1-phenylpropan-2-amine

GPTKB entity

Predicate	Object
gptkbp:instanceOf	gptkb:chemical_compound gptkb:amphetamine
gptkbp:alternativeName	gptkb:amphetamine
gptkbp:ATCCode	N06BA03
gptkbp:boilingPoint	215 °C
gptkbp:CASNumber	537-46-2
gptkbp:drugClass	gptkb:stimulant gptkb:anorectic
gptkbp:eliminationHalfLife	9–12 hours
gptkbp:has_discovered_by	gptkb:Nagai_Nagayoshi
gptkbp:has_discovered_year	1893
gptkbp:has_excretion	urine
gptkbp:has_metabolism	liver
gptkbp:has_parent_compound	gptkb:amphetamine
gptkbp:hasInChIKey	KWTSXDURSIMDCE-UHFFFAOYSA-N
gptkbp:hasMolecularFormula	C10H15N
gptkbp:hasSMILES	CC(CC1=CC=CC=C1)NC
gptkbp:hasUNII	44RAL3456C
gptkbp:IUPACName	gptkb:N-methyl-1-phenylpropan-2-amine
gptkbp:legalStatus	gptkb:Narcotic_(Japan) gptkb:Schedule_8_(Australia) Class A drug (UK) Schedule II controlled substance (US) Schedule I controlled substance (Canada)
gptkbp:medicalUse	treatment of ADHD treatment of obesity
gptkbp:meltingPoint	170 °C (hydrochloride salt)
gptkbp:PubChem_CID	10367 10836
gptkbp:relatedTo	gptkb:ephedrine gptkb:MDMA gptkb:pseudoephedrine
gptkbp:routeOfAdministration	oral intravenous smoked insufflated
gptkbp:sideEffect	insomnia addiction potential increased blood pressure
https://www.w3.org/2000/01/rdf-schema#label	N-methyl-1-phenylpropan-2-amine